|
 |
|||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||
|
Study of experimental drug tedizolid also found fewer daily doses needed By Robert Preidt
TUESDAY, Feb. 12 (HealthDay News) -- A short course of treatment with a newer antibiotic called tedizolid works as well against bacterial skin infections as longer treatment with the antibiotic linezolid, a new study finds. "These infections, which include cellulitis and other wound infections, can be life threatening," noted one expert not connected to the study, Dr. Michele Green, a dermatologist at Lenox Hill Hospital, in New York City. "Because so many of these infections have become antibiotic-resistant, the development of a novel antibiotic which is effective is very important," she added. The new phase 3 clinical trial included 667 adult patients in North America, Latin America and Europe who received either 200 milligram pills once a day of tedizolid phosphate for six days, or 600 mg of linezolid every 12 hours for 10 days. The drugs showed similar levels of effectiveness after two to three days and after 11 days, according to the study in the Feb. 13 issue of the Journal of the American Medical Association. Side effects, mostly mild or moderate, occurred in nearly 41 percent of patients taking tedizolid and about 43 percent of those taking linezolid. Rates of serious side effects were low and similar in both groups, according to a journal news release. The study was led by Dr. Philippe Prokocimer, of Trius Therapeutics Inc., San Diego, which makes tedizolid and funded the study. According to Green, the study suggests tedizolid is "a reasonable alternative" to the older drug, especially for infections with MRSA (methicillin-resistant Staphylococcus aureus), "which is a growing problem, due to antibiotic resistance and the continued use of prolonged antibiotics." Another expert agreed. Dr. Scott Gorenstein is an expert in wound healing therapies at Winthrop-University Hospital in Mineola, N.Y. He said it is important to find shorter-course antibiotic therapies to help reduce antibiotic resistance and the risk for complications. Gorenstein, who is also clinical director of the hospital's Hyperbaric Medicine Program, called the study "a great starting point" for further research to confirm these findings. More information MedlinePlus has more about skin infections. SOURCE: Michele Green, M.D., dermatologist, Lenox Hill Hospital, New York City; Scott Gorenstein, M.D., clinical director, Hyperbaric Medicine Program, Winthrop-University Hospital, Mineola, N.Y.; Journal of the American Medical Association, news release, Feb. 12, 2013 Health News Copyright © 2013 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=673332
|
